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Objectives: To investigate the relationship between ecstasy use and mental disorders in a 
representative sample of adolescents and young adults. Method: Data for this investigation were 
drawn from the Early Developmental Stages of Psychopathology (EDSP) study, an 
epidemiological-longitudinal study in which 14-24 year-olds were examined prospectively over a 
period of about 4 years. Results are based on N=2462 participants who completed the whole study 
period and for whom drug use behavior could be determined. Results: (1) Ecstasy users, compared 
with non-users, were at significantly increased risk of DSM-IV substance related disorders, 
including alcohol use disorders (52.6 vs. 15.6%; OR=5.6, 95% CI=3.8-8.1). Further, ecstasy users 
also had a higher risk of alcohol use disorders, when compared with users of other illicit 
substances (52.6 vs. 40.3%; OR=1.7, 95% CI=1.1-2.4). (2) Ecstasy users had significantly higher 
rates for almost all DSM-IV mental disorders examined when compared with non-users (any non-
substance use disorder: 68.7 vs. 44.5%; OR=3.1, 95% CI=2.1-4.4) and compared with users of 
other illicit drugs (any non substance use disorder: 68.7 vs. 55.5%; OR=1.8, 95% CI=1.2-2.6). (3) 
Ecstasy users also reported significantly higher rates of prescription medicine use, though they did 
not use more medical services than non-drug users. (4) Analyses of temporal patterns of ecstasy 
use and disorder onset revealed that the first use of ecstasy was secondary to the onset of DSM-IV 
mental disorders in the majority of cases. Still, subjects with mental disorders at baseline also 
showed a significantly increased risk for initiation of ecstasy use during the 4-year follow-up 
period. Conclusions: Care should be taken in cross sectional studies in interpreting mental disorder 
signs and symptoms merely as a consequence of ecstasy use, as ecstasy use might be associated 
with the use of multiple substances, and onset of mental disorder is more likely to precede rather 
than to follow use of ecstasy and related substances.    
 




1. Introduction  
 
The World Health Organization (WHO) in 1996 acknowledged that 3,4-methylendioxy-
N-methyl-amphetamin (MDMA), known as ‘Ecstasy’, and similar substances are 
becoming an established part of youth culture in some countries and that use is not 
generally perceived as dangerous (WHO, 1996). Epidemiological studies reveal that 
ecstasy use is common in the general population. A community survey of 3021 
adolescents and young adults in the Munich (Germany) metropolitan area revealed in 
1995 that 4% of the male and 2.3% of the female respondents aged 14-24 had used 
ecstasy, in addition to 3.6% of men and 1.6% of women who had used ecstasy-related 
substances (chemically related compounds, including amphetamines) (Perkonigg et al., 
1998a). This rate was at least a 2-fold increase, compared with findings from a 1990 
survey (Schuster et al., 1998), suggesting a considerable elevation in incidence within the 
past decade.  
 
Pharmacologically, ecstasy pills should contain MDMA. However, Galliot-Guilley et al. 
(1999) showed that the generic term ‘ecstasy’ actually covers a wide variety of molecules 
with variable formulations. Their findings suggest only 22% of ecstasy pills to contain any 
MDMA. Similar results have been reported by other groups. In fact, ecstasy pills often 
contain other stimulating substances including caffeine, amphetamine and amphetamine 
derivatives, e.g. designer drugs, such as 3,4-methylendioxy-N-ethyl-amphetamin (MDE), 
3,4-methylendioxy-amphetamin (MDA) (Sherlock et al., 1999; Christophersen, 2000).  
 
Originally, ‘ecstasy’ was considered a relatively benign substance (Chesher, 1990; 
Solowij et al., 1992). Recent reports, however, show that use of ecstasy and related 
compounds may be associated with problems similar to those experienced by users of 
cocaine, including dependence (Morgan, 1998; Jansen, 1999). In addition to its rewarding 
effects, ecstasy’s psychological effects may include cognitive deficits, confusion, 
depression, sleep problems, anxiety, and paranoia, sometimes lasting weeks after 
discontinuation of ecstasy use (Krystal et al., 1992; Wodarz and Böning, 1993; Parrott et 
al., 1998). Physical effects of ecstasy use may include muscle tension, involuntary teeth-
clenching, nausea, blurred vision, faintness, and increases in heart rate and blood pressure 
(Liester et al., 1992; Gouzoulis-Mayfrank and Hermle, 1994; Thomasius et al., 1997; 
Schütz and Soyka, 1998; Vollenweider et al., 1998).  
 
It has been a commonly held belief that recreational ecstasy use was infrequent with 
intermittent oral administration of little health concern (Beck and Rosenbaum, 1994). 
Reports have not only questioned the benign ‘pharmacological’ nature of ecstasy, but also 
its context. In an Italian study, Schifano and colleagues (Schifano et al., 1998) examined 
150 ecstasy users presenting to the Padova Addiction Treatment Unit between 1991 and 
1996 and found ecstasy use to be highly associated and intertwined with an extensive use 
of other licit and illicit substances. Furthermore, extensive psychopathology was found in 
this sample, including depression (32%), psychotic disorders (28%), cognitive impairment 
(27%), bulimia (24%) and panic attacks (12%). The authors concluded that 
psychopathology was substance induced but their findings are not generalizable to the 
community due to self-selection into treatment. Topp et al. (1999) found extensive 
polydrug use to be the norm among 329 ecstasy users in an Australian sample. 
Specifically, an average of eight physical and four psychological symptoms were 
attributed to ecstasy use within the last 6 months and one-fifth had sought professional 
help for a problem associated with ecstasy use. More recently, Pederson and Skrondal 
(1999) found that, among a sample of 10 812 adolescents aged 14-17 years in Oslo, 
ecstasy use was initiated subsequent to already existing use of other illicit substances, 
indicating that it was introduced late in a hypothesized drug use sequence. 
Epidemiological studies in unselected samples on the association between ecstasy use 
with DSM-IV mental disorders are lacking.  
 
In sum, these findings suggest that use of ecstasy or related substances may be embedded 
in polydrug use and that use of ecstasy may be associated with significant mental 
problems and a wide range of mental disorders. However, results to date are limited in 
their generalizability to the community in at least two ways. First, previous studies are 
based solely on clinical samples. Therefore, it is not known whether the observed 
associations between ecstasy use and mental disorders exist among those who use ecstasy 
and do not seek help. Second, previous studies are cross-sectional. Therefore, it cannot be 
determined whether mental disorders precede or follow the initiation of ecstasy use. The 
current study allows us to fill this gap by using a prospective-longitudinal design to 
examine the relationship between ecstasy use and mental disorders among a representative 
sample of more than 3000 adolescents and young adults in the community.  
 
The aims of this paper are 3-fold: (1) to evaluate the co-occurrence of ecstasy and related 
illicit drug use and DSM-IV mental disorders in a representative community sample of 
adolescents and young adults, unbiased by treatment selection or self referral; (2) to 
investigate the association between ecstasy use and utilization of medical and 
psychological services, as well as prescription medication use; (3) to examine whether use 
of ecstasy and related compounds precedes or follows the onset of mental disorders.  
 
2. Methods  
 
2.1. Design  
 
The Early Developmental Stages of Psychopathology study (EDSP) is a prospective-
longitudinal design based on a representative community sample of adolescents and young 
adults living in the Munich area, aged 14-24 years at baseline. The EDSP consists of a 
baseline investigation (T0), two follow-up investigations (T1, T2) and an independent 
parent survey. Detailed descriptions of the design have been presented elsewhere (see 
Wittchen et al., 1998a; Lieb et al., 2000).  
 
2.2. Sample  
 
The EDSP sample was drawn randomly from the 1994 government population registries 
of residents in metropolitan Munich and the surrounding counties with an expected age 
range for the sampled subjects between 14 and 24 at the time of the baseline interview in 
1995. As the study was designed as a longitudinal panel with special interest in early 
developmental stages of psychopathology, 14-15 year-olds were sampled at twice the 
probability of people 16-21 years of age, and 22-24 year-olds were sampled at half the 
probability of the 16-21 year-olds. From the total of 4809 sampled individuals, 4263 were 
located and determined to be eligible for the study. Sampled individuals who were not 
located were disproportionately older. In comparison to located subjects, subjects who 
could not be located had either moved outside the metropolitan Munich area in the time 
interval between their registration and the beginning of the study in 1995 (8.8%) or could 
not be assessed with the listed address during the field work period (2.4%). From the 4263 
individuals a total of 3021 interviews were completed at baseline (T0) resulting in a 
response rate of 71%. Refusal to participate (18.2%) was by far the most frequent reason 
for non-response, followed by a reported lack of time (3.3%), failure to contact anyone in 
the identified household (3.1%), and failure to contact the sampled individual in the 
household (3.0%). The demographic distribution of the sampled population and the 
respondents has been reported elsewhere (Wittchen et al., 1998a,b). Briefly, at baseline 
almost three-quarters of the population were students, 36% at the secondary level and 
35% at university. Nearly twothirds (64%) of the sample were living with their parents 
and 23% were living alone. Two follow-up investigations (T1+T2) were completed after 
the initial baseline assessment, covering an overall period of 42 months (range: 34-50 
months).  
 
The first follow-up (T1) was conducted in 1996/1997 and was confined to the younger 
subsample (aged 14-17 years at baseline); 1228 interviews were completed, giving a 
follow-up response rate of 88%. The second follow-up (T2) included all baseline 
respondents and was conducted in 1998-99, an average of 42 months after the baseline 
investigation (range 34-50 months); the response rate was 84%. Drug use behavior could 
be determined in at least one of the assessment stages for 2462 participants. Noteworthy 
changes in sociodemographic characteristics from baseline to second followup were found 
only for school/employment status (T2: secondary school: 13%; employed: 36%) and 
living arrangements (with parents: 40%; with partner: 23%). At second follow-up, the 
most frequent reasons for nonresponse were refusal to participate (9.2%), failure to 
contact the individual (2.7%) and lack of time (1.5%).  
 
2.3. Measures  
 
2.3.1. Diagnostic assessment  
 
Face-to-face computer assisted interviews were administered by a highly experienced 
survey staff consisting of 57 clinical interviewers, most of whom were clinical 
psychologists who had extensive experience in diagnostic interviewing including the 
computer assisted version of the Munich-Composite International Diagnostic Interview 
(M-CIDI; Wittchen and Pfister, 1997). At baseline, 25 professional health research 
interviewers recruited from a survey company were additionally involved. Formal training 
with the M-CIDI took place for 2 weeks, followed by at least ten closely monitored 
practice interviews and additional 1-day booster sessions throughout the study.  
 
The M-CIDI is an updated version of the WHO’s CIDI version 1.2 (WHO, 1990) that 
incorporates questions assessing DSM-IV (APA, 1994) and ICD-10 (WHO, 1994) criteria. 
The M-CIDI allows for the standardized assessment of symptoms, syndromes and 
diagnoses of a wide range of DSM-IV substance use and mental disorders (and 
additionally various subtypes of main disorders) along with information about onset, 
duration, and clinical and psychosocial severity. In the baseline investigation, the lifetime 
version of the M-CIDI was used to assess lifetime and 12-month information. For the two 
follow-up investigations, the M-CIDI was modified to cover the 12-month period prior to 
the follow-up interview as well as the remaining interval between the investigations (12-
month-interval-version). In all assessments the M-CIDI was supplemented by a separate, 
individual booklet for each respondent that included several scales and questionnaires for 
assessing psychological constructs that are relevant to our study. A detailed overview and 
characterization of the constructs and assessment scales used has been presented 
elsewhere (Wittchen et al., 1999; Höfler et al., 1999; Lieb et al., 2000). The reliability and 
validity of the M-CIDI have been established and reported in greater detail elsewhere 
(Lachner et al., 1998; Reed et al., 1998; Wittchen et al., 1998c).  
 
In all three waves, individuals were contacted first by letter and subsequently by telephone 
to arrange a meeting. Most interviews (including the assessments of questionnaires) took 
place in the homes of the respondents or, in some instances, at another location preferred 
by the respondents. Participants provided informed consent.  
 
2.3.2. Assessment of drug use  
 
The section of the face-to-face M-CIDI which assesses illicit drug use has already been 
described in detail in previous publications (Lachner et al., 1998; Perkonigg et al., 1998b; 
Schuster et al., 1998). Therefore, only a brief summary will be given here. In the initial 
screening part of the drug section, the respondent is first asked whether he or she is 
willing to respond to these questions openly (‘commitment probe’). Only very few (less 
than 1% of the sample) denied this question; in these cases the complete substance section 
was skipped. The section continues with a comprehensive list of eight types of substances 
(e.g. cannabis, opioids) along with the most frequent market and street names. The 
respondent is asked whether he or she has ever taken one of the presented substances. 
Whenever the respondent acknowledged having used at least one of the substances on at 
least five occasions, the section continued with a further assessment of quantity and 
frequency of use as well as associated abuse or dependence symptoms. In addition to the 
drugs from the list, the respondent is free to add any other substance. In determining 
ecstasy use, the wide range of names used for it and the user’s lack of precise knowledge 
about the chemically active ingredients make accurate assessment difficult. Simply 
inquiry about ‘ecstasy’ use might lead to an underestimate. Therefore, we assessed not 
only respondents capable of making reasonably clear indications about specifically using 
ecstasy but also those using other terms or other types of stimulants likely to be ecstasy-
related drugs (such as MDE, MDA, and also including amphetamines or speed). All 
subjects having used a drug at least five times ever are then interviewed with the full 
diagnostic section to establish the presence or absence of all DSMIV diagnostic criteria 
for abuse or dependence.  
 
2.4. Assessment of indicators of medical complications  
 
At second follow-up (an average of 42 month later), indicators of medical complications 
were assessed by evaluating respondents’ recent use of health services as well as current 
intake of medications. Assessment of health service utilization was determined by asking 
whether and how often they went to see any of the professionals presented on a separate 
list (e.g. psychiatrist, internist) during the past 12 months. Current medication use was 
assessed by asking respondents if they had used any of the medications presented on a list 
(e.g. pain killers) during the last 4 weeks.  
 
2.5. Analysis of the data  
 
Based on the respondents information given in the different waves for the drug use 
section, this paper divides the sample into three mutually exclusive groups according to 
their lifetime drug use status at second follow-up: (1) ecstasy and related drugs: this group 
includes all respondents who reported at either baseline or the follow-up assessments at 
least one intake of ecstasy or any ecstasy-related drug, (2) other illicit drugs: this group 
includes all respondents who used at least once in their life any illicit drug (e.g. cannabis, 
cocaine, opioids), but never used ecstasy or any ecstasy-related drug, and (3) no illicit 
drug: this group includes all respondents who reported neither use of any illicit drugs at 
baseline nor at the follow-up assessments. Cumulative lifetime incidences of DSM-IV 
mental disorders, which were calculated by adding baseline (T0) and follow-up (T1, T2) 
incident cases, were used for the analyses of lifetime co-morbidities between DSM-IV 
mental disorders and use of ecstasy and related drugs. Here, odds ratios (ORs) were 
calculated as measures of strength of associations. All associations were adjusted for age, 
gender and socio-demographic effects (McCullagh and Nelder, 1989). In order to exclude 
the possibility that positive associations are artifactual because the younger cohort has 
been assessed three times, all calculations were tested for an interaction effect with age 
cohort and in case of significance were run separately within each cohort. In terms of 
temporal patterns of comorbidity, use of ecstasy and related drugs was termed as 
‘temporally primary’ whenever their age of first use preceded the age of onset of the co-
morbid DSM-IV mental disorder. Conversely, when the age of first use occurred after the 
age of onset of the comorbid disorder, use of ecstasy and related drugs was said to be 
‘temporally secondary’.  
 
To account for the different sampling probabilities, non-contact and non-response, a 
relative weight was used in all analyses that adjusts the data by age, sex and geographic 
location to match the distribution of the sampling frame. A more detailed description of 
the EDSP weighting procedure is presented elsewhere (Wittchen et al., 1998a; Lieb et al., 
2000).  
 
All statistical analyses were performed using the software package STATA (Stata Corp., 
1999), which applies the Huber-White sandwich matrix for robust estimates of standard 
errors and confidence intervals in the case of weighted data (Royall, 1986). The present 
analyses are based on the data for the respondents who completed the whole 4-year study 
period and for whom drug use behavior could be determined (N=2462; 97% of the final 
follow-up sample). Subjects for whom lifetime ecstasy use could not be determined were 
excluded from the analyses (N=86).  
 
3. Results  
 
3.1. Estimated cumulative lifetime use of ecstasy and other illicit substances  
 
A total of 211 respondents (8.9%; percentages are adjusted by weights for sampling 
design) reported having used either ecstasy (6.6%) or any ecstasy-related substance 
including amphetamine (2.3%) at least once in their lifetime. Males reported use of 
ecstasy more frequently than females (10.4 vs. 7.5%; OR=1.4; 95% CI=1.0-2.0).  
 
Almost 40% (39.7%) of the sample used illicit substances other than ecstasy, 
amphetamine or related compounds at least once, with higher rates in males than females 
(44.8 vs. 34.7%; OR=1.5; 95% CI=1.3-1.8). No differences in drug use rates were found 
between the younger (the 14-17 year-olds at baseline) and the older (18-24 year-olds at 
baseline) age groups. Fig. 1 shows the age-specific cumulative incidences for use of 
ecstasy and related substances in males and females.   
 
3.2. Socio-demographic correlates  
 
At baseline, only few socio-demographic characteristics were found between respondent 
who had and had not used ecstasy (results not shown but available on request). Higher 
education (Gymnasium, a secondary education, which prepares students for University) 
was found to be associated with a decreased likelihood of using ecstasy, when ecstasy 
users were compared with respondents who never used illicit substances. There was no 
significant difference in socio-demographics from the baseline assessment comparing 
ecstasy users and users of other illicit substances.  
 
When these analyses were re-run using socio-demographics from the second follow-up 
investigation (controlling for age and gender), results differed (Table 1). University level 
education was significantly associated with lower ecstasy use, when comparing ecstasy 
users both to non-users and to users of other illicit substances. In addition, being 
unemployed and being from a lower social class (self-attributed) was associated with 
increased risk of ecstasy use, in comparison both to nonusers and users of other illicit 
substances. Comparing users of ecstasy to non-drug users, increased risk of use was 
further significantly associated with living alone and not being married, especially if 
separated, divorced or widowed.  
 
Having established a number of significant associations of ecstasy use and socio-
demographic factors, we estimated ORs controlled for possible confounders: age, gender, 
education living arrangements, and financial situation. Controlled ORs and OR not 
controlled for these variables showed no more than marginal differences, thus we report 
results based on controlled ORs only.  
 
3.3. Associations with substance use and substance use disorder  
 
As presented in Table 2, the majority of respondents (68.7%) who ever used ecstasy 
reported a history of at least one DSM-IV mental disorder. Users of ecstasy and related 
compounds also reported higher proportions of alcohol use disorders (52.6 vs.15.6%; 
OR=5.6) and nicotine dependence (53.2 vs. 10.4%; OR=9.9) than respondents who never 
used illicit substances. Users of ecstasy and related compounds were also found to reveal 
higher proportions when compared with users of other illicit substances: alcohol use 
disorders (52.0 vs. 40.3%; OR=1.7) and nicotine dependence (53.2 vs. 37.1%; OR=1.8). A 
comparison of abuse and dependence diagnoses in both substance using groups indicates 
that use of illicit substances is considerably higher in ecstasy users (43.7 vs. 11.7%; 
OR=6.4). Further, almost all users of ecstasy and related compounds (93%) also reported 
the use of cannabis. Proportions for concommittant cannabis use were similarly high in 
other illicit drug users (95%). Opioids had been used by 3.9% of the users of illicit 
substances with no experience with ecstasy, while 21.4% of the ecstasy users reported 
experience with opioids. Similarly, 6.5% of the users of illicit substances with no 
experience with ecstasy had used cocaine, while 59.1% of those with a history of ecstasy 
use reported experience with cocaine (Results not shown, but available on request).  
 
3.4. Associations with mental disorders  
 
When investigating DSM-IV non-substance mental disorders among ecstasy users, 
increased proportions were found as compared with non-users for most mental disorders, 
including affective disorders (OR=2.6), anxiety disorders (OR=2.4), somatoform disorders 
(OR=1.8), and eating disorders (OR=3.6). Most of these associations remain statistically 
significant (or close to being statistically significant) when associations of users of ecstasy 
and related substances were compared with those using other illicit substances (but not 
ecstasy), yet the associations appear to be less pronounced.  
 
Suicidal ideation was significantly more often reported by users of ecstasy and related 
compounds than by respondents without any use of illicit substances (OR=2.2).  
 
All analyses were examined to detect cohort effects between the younger cohort (age 14-
17 at baseline) and the older cohort (age 18-24 at baseline). Among the large number of 
interactions investigated a total of four significant findings could be detected: alcohol 
abuse and bipolar I disorder had higher ORs in the younger cohort. Any somatoform 
disorder and especially pain disorder had higher ORs in the older cohort. Given the small 
number and unsystematic character of interactions between these two cohorts, we 
conclude that no systematic cohort effect could be detected.  
 
3.5. Health care utilization  
 
Although ecstasy users reported slightly higher proportions of primary care and specialist 
medical services only one comparison was significant (Table 3). Users of ecstasy and 
related compounds more often sought the help of psychologists (OR=2.3).  
 
Table 3 also reveals higher proportions of use of prescription medications of users of 
ecstasy compared with respondents who never used illicit substances, especially for use of 
pain killers (OR=1.9), sleeping pills (OR=4.2), sedatives (OR=2.3), psychotropics 
(OR=9.0) and stimulants (OR=6.7). No significant differences in use of other medications 
were found, except for vitamins (OR=1.5). Comparisons of users of ecstasy and related 
compounds and users of other illicit substances again revealed significantly increased use 
rates for pain killers (OR=1.6), sleeping pills (OR=2.2), psychotropics (OR=3.3) and 
stimulants (OR=4.9). No age cohort effect was detected.  
 
3.6. Temporal sequence in onset of ecstasy use and DSM-IV mental disorders  
 
Table 4 summarizes temporal sequence of onset of ecstasy use and DSM-IV mental 
disorders. Overall, the onset of mental disorders clearly occurred prior to the first use of 
ecstasy in the large majority (88.4%) of cases. This pattern persists even if other substance 
related disorders are excluded from the analysis of ecstasy use and onset of mental 
disorders (80.4%). The most frequent mental disorders occurring prior to the onset of the 
first use of ecstasy were: specific phobia (98.4%), social phobia (76.6%), alcohol 
abuse/dependence (78%) and somatoform conditions (73.2%). In a smaller percentage of 
cases, the onset of mental disorders occurred subsequent to the initiation of ecstasy use. 
Most frequent secondary mental disorders following onset of ecstasy use were: major 
depression (40%), phobia NOS (29.8%), panic disorder (22.9%), agoraphobia (25.7%), 
generalized anxiety disorder (25.3%) and eating disorder (28.5%). In order to investigate 
the temporal pattern of onset with a more rigorous statistical approach, we selected 
subjects with and without ecstasy use at T0 and compared the number who developed 
mental disorders. We found no significant difference in the incidence of mental disorders 
between these two groups (OR=2.9; 95% CI=0.8-9.7), despite the elevated point estimate 
among those with ecstasy use at T0 (57.2 vs. 36.4%). This may be due to small cell size 
(N=13, Nw=17). Comparing patterns of incidence of ecstasy use among those with, 
compared with those without, a history of mental disorder at T0, we found a significant 
difference (OR=2.6, 95% CI=1.7-4.1) with a higher point estimate of ecstasy use among 
those with a history of mental disorder (6.0%) compared with those with no mental 
disorder (3.2%).  
 
4. Discussion  
 
Based on a 4-year prospective longitudinal (-) community study of 3021 subjects aged 14-
24 at baseline the present paper confirmed earlier findings (Perkonigg et al., 1999; 
Schuster et al., 1998; Sydow et al., 2002), that the use of ecstasy and related substances is 
widespread in the community. Thus, at time in point of the second follow-up 
investigation, we observed a cumulative lifetime incidence rate of ecstasy use of 8.9% 
(males, 10.4%; females, 7.5%) of the total sample. The use of a prospective-longitudinal 
design with an unselected community sample, and comprehensive standardized substance 
use-related and psychopathological assessments, offers the opportunity to study the 
predictors, correlates and consequences of ecstasy use with findings that are generalizable 
to the community.  
 
The overall findings from the study confirm that ecstasy use constitutes a complex and 
multifaceted phenomenon in our sample. Several findings should be highlighted:  
 
1) The study supports recent findings that the majority of ecstasy users are polydrug users 
as well; 53% fulfill criteria for nicotine dependence, 44% meet criteria for any illicit 
substance use disorder (abuse: 34%, dependence: 22%) and 53% meet criteria for an 
alcohol use disorder. Thus, users of ecstasy and related compounds are at a moderately 
increased risk for abuse of and dependence on licit drugs, compared to those without 
ecstasy use, and a more pronounced risk for abuse and dependence of illicit drugs, 
compared to those who have not used ecstasy. This finding is not surprising when the 
comparison group consists of subjects with no experience in using any illicit substance, 
but also persists even when users of ecstasy and related substances were compared with 
illicit drug users. The excessive use of prescription medicines among ecstasy users, in 
particular pain killers, sedatives, sleeping pills, and other prescribed psychotropics, should 
also be emphasized especially in view of the fact that they did not report increased rates of 
health service utilization, with the exception of more visits to psychologists. This might 
indicate that ecstasy users are more likely than people with no drug use to misuse 
prescription drugs.  
 
2) It is also noteworthy that socio-demographic factors at baseline do not appear to predict 
first use of ecstasy at baseline in this sample. However, at follow-up we found several 
significant associations between demographic factors and ecstasy use. These included 
poorer educational status, lower social class, unemployment and being separated, 
divorced, or widowed. This finding might signal that these socio-demographic factors are 
more likely to be a correlate or consequence of ecstasy use than a causal risk factor for 
initiation. That the sociodemographic correlates of other drug use (e.g. cannabis) 
resembled those of ecstasy use but again did not predict it at baseline offers additional 
evidence in support of this tentative conclusion.  
 
3) The study’s primary aim was to investigate the association between use of ecstasy and 
related substances and the risk of non-substance-related mental disorders. Ecstasy use was 
associated with a substantially increased risk for almost all mental disorders examined. 
Specifically, 69% had at least one mental disorder. In comparison to non drug users, the 
odds of having a mental disorder was 3- fold among ecstasy users, compared with non 
users, and almost 2-fold, compared with users of other illicit substances. Ecstasy use was 
also strongly associated with having two or more lifetime mental disorders in comparison 
to both reference groups. In detail, 51% of all ecstasy users had a current or past diagnosis 
of anxiety disorders, 43% of somatoform disorders, and 40% of any affective disorder. 
Compared with non-drug users and other illicit substance users the strongest associations 
were between ecstasy use and panic attacks and panic disorder, general anxiety disorder 
(GAD), posttraumatic stress disorder (PTSD), eating disorders and major depression.  
 
4) Using the available longitudinal data, the examination of the temporal relationship 
between initiation of ecstasy use and onset of DSM-IV mental disorders was approached 
by two strategies. In the first set of analyses, we simply compared ages of onset of ecstasy 
use and age of onset of mental disorders. Results of this comparison suggest that the onset 
of DSM-IV mental disorders clearly precedes the onset of first ecstasy use in the majority 
of cases. Among those with mental disorders and ecstasy use, most frequently phobias 
(98-55%, depending on type of phobic disorder), somatoform disorders and syndromes 
(73%), dysthymia (69%), and disorders of the panic/agoraphobic spectrum (61-63%) 
preceded the onset of ecstasy use. It is also noteworthy, however, that mental disorders did 
not precede initiation of ecstasy use in all cases. In fact, ecstasy users were also found to 
develop mental disorders after first use of ecstasy had occurred. The most common 
secondary mental disorders were major depression (40%), panic/agoraphobia/phobia NOS 
disorders (30-23%), generalized anxiety and eating disorders. Further, the proportion 
(26%) of those developing secondary illicit drug abuse or dependence is also noteworthy. 
We then performed a two-step second set of analyses toward this end, using a more 
complex statistical approach, due to the complex nature of the temporal relationship 
between onset of mental disorders and initiation of ecstasy use. The findings resulting 
from this methodological approach were consistent with and added greater depth to the 
findings of our initial analyses. First, with a prospective analysis of the data, we confirmed 
that subjects with a mental disorder at baseline were indeed more likely to begin using 
ecstasy, compared with subjects not diagnosed with a mental disorder at baseline. Second, 
we found that there was a higher incidence of mental disorders during follow-up among 
those with compared to those without ecstasy use at baseline, although this finding failed 
to reach statistical significance.  
 
To conclude, despite the fact that there is a complex and powerful relationship between 
ecstasy use and mental disorders, these findings highlight that caution should be advised 
in assigning an overly specific causal role for ecstasy as a primary risk factor for the onset 
of mental disorders, even though neuroscientific findings provide quite plausible 
explanations for such a mechanism. Our results corroborate the finding that ecstasy users 
are characterized by very high levels of DSM-IV mental disorders and psychological 
problems. The strong association can be explained in a number of ways. Two basic causal 
pathways can be assumed: (1) mental disorders lead to substance use, e.g. in the form of 
‘self-medication’, or (2) mental disorders are a consequence of substance use. Previous 
cross-sectional studies have argued consistently for the second option, based on 
contemporaneous reports that ecstasy seems to induce persistent neurological changes. 
Related to this, research has indicated that MDMA use may damage brain serotonin 
neurons (Ricaurte et al., 1985, 1988), which may play a role in mediating behavior 
disturbances and might lead to mental disorders (Allan et al., 1993; McCann et al., 1994; 
Scheffel et al., 1998; Sprague et al., 1998; Vollenweider et al., 1998; Ricaurte et al., 2000; 
McCann et al., 2000). According to this approach, ecstasy-induced psychopathology 
seems to be pharmacologically plausible. However, our findings which are based for the 
first time on a representative prospective-longitudinal sample support strong evidence for 
the first pathway, i.e. that mental disorders lead to the use of ecstasy, as the more 
dominant picture of our results suggests that subjects with existing anxiety, somatoform 
and depressive disorders are at high risk for ecstasy use and the development of other licit 
and illicit substance use disorders.  
 
Limitations: These findings are based on a representative sample of the general population 
in Munich, Germany. It should be noted, however, that while these findings are consistent 
with the only previous population based study on ecstasy use and comorbidity (Pederson 
and Skrondal, 1999), their generalizability to demographically diverse populations may be 
limited. Therefore, these findings need replication in other population-based samples. 
While the study was prospective in nature, use of substances prior to baseline interview 
was necessarily retrospective and may, therefore, be subject to recall bias. We used DSM-
IV diagnoses, therefore, comparison of these findings to results of studies that use 
different psychiatric nosological classification systems are cautioned. Finally, we 
summarized ecstasy and ecstasy-related substance use in these analyses. While we found 
no significant differences between those who reported use of ecstasy and ecstasy-like 
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